GlassScriptPhysician profile
Gregory R Mesa
NPI 1023144193
$2,534.14
in general payments reported to CMS, 2019-2025
21 companies · $2,534 in 2025
The $2,534 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $604.58 | 2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $376.53 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $291.62 | 2025 | |
| Amgen INC. | $160.52 | 2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $151.96 | 2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.93 | 2025 | Caplyta |
| Astellas Pharma US INC | $131.78 | 2025 | Veozah |
| Pfizer INC. | $119.63 | 2025 | |
| Lundbeck LLC | $104.73 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $103.45 | 2025 | Rexulti |
| Exact Sciences Corporation | $63.41 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Cycle Pharmaceuticals INC | $48.93 | 2025 | Sajazir |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.02 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.99 | 2025 | Jardiance |
| Shield Therapeutics INC | $35.70 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $31.83 | 2025 | Rybelsus, Ozempic |
| Eisai INC. | $24.24 | 2025 | |
| Acadia Pharmaceuticals INC | $21.62 | 2025 | Nuplazid |
| Vanda Pharmaceuticals INC. | $20.35 | 2025 | Hetlioz, Fanapt |
| Dexcom, INC. | $16.67 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $15.65 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.